Based on the analysis of Allovir's profitability, liquidity, and operating efficiency, Allovir is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, Allovir's Other Current Assets are relatively stable compared to the past year. As of 12/16/2024, Total Liabilities is likely to grow to about 56.5 M, while Total Current Liabilities is likely to drop slightly above 21.2 M. Key indicators impacting Allovir's financial strength include:
Investors should never underestimate Allovir's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Allovir's cash flow, debt, and profitability to make informed and accurate decisions about investing in Allovir.
Net Income
(180.9 Million)
Allovir
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Change To Inventory
Change Receivables
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Other Cashflows From Investing Activities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Lease Obligations
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Capital Stock
Net Working Capital
Short Long Term Debt Total
Property Plant And Equipment Net
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Short Term Debt
Property Plant Equipment
Retained Earnings Total Equity
Capital Surpluse
Non Current Liabilities Other
Net Interest Income
Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Tax Provision
Cost Of Revenue
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past Allovir Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Allovir's financial statements are interrelated, with each one affecting the others. For example, an increase in Allovir's assets may result in an increase in income on the income statement.
Allovir competes with Anebulo Pharmaceuticals, Mineralys Therapeutics,, AN2 Therapeutics, Aerovate Therapeutics, and Adagene. Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Allovir's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Allovir's current stock value. Our valuation model uses many indicators to compare Allovir value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Allovir competition to find correlations between indicators driving Allovir's intrinsic value. More Info.
Allovir is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Allovir's Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Allovir by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Allovir Systematic Risk
Allovir's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Allovir volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Allovir correlated with the market. If Beta is less than 0 Allovir generally moves in the opposite direction as compared to the market. If Allovir Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Allovir is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Allovir is generally in the same direction as the market. If Beta > 1 Allovir moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Allovir Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Allovir's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Allovir growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Allovir help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Allovir. We use our internally-developed statistical techniques to arrive at the intrinsic value of Allovir based on widely used predictive technical indicators. In general, we focus on analyzing Allovir Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Allovir's daily price indicators and compare them against related drivers.
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.